Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 37

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 37
---
 10X GENOMICS, INC.342025 PROXY STATEMENT
Compensation
Committee Report

The Compensation Committee has reviewed and discussed with management the disclosures contained in the following “Compensation Discussion and Analysis.” Based on this review and discussion, the Compensation Committee recommended to the board of directors that the section titled “Compensation Discussion and Analysis” be included in this Proxy Statement for the 2025 Annual Meeting.

Respectfully submitted,

THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF 10X GENOMICS, INC.

John R. Stuelpnagel, Chairman
Kimberly J. Popovits

#### 10X GENOMICS, INC.352025 PROXY STATEMENT
Executive Officers

The following table sets forth certain information about our executive officers and their respective ages as of April 14, 2025. Officers are elected by the board of directors to hold office until their successors are elected and qualified.

| Name(1)             |     | Age |     | Position                                         |
| Serge Saxonov       |     |  48 |     | Chief Executive Officer and Director             |
| Adam S. Taich       |     |  50 |     | Chief Financial Officer                          |
| Benjamin J. Hindson |     |  50 |     | Chief Scientific Officer, President and Director |
| Eric S. Whitaker    |     |  58 |     | Chief Legal Officer                              |

(1) Mr. Justin McAnear resigned as our chief financial officer effective as of August 12, 2024 and separated from the company effective August 30, 2024.

For the biographies of Drs. Saxonov and Hindson, see “Matters to Come Before the 2025 Annual Meeting—Proposal One—Election of Directors—Continuing Directors.”

|                         |     | Adam S. Taich has served as our Chief Financial Officer since August 2024. Mr. Taich previously served as Chief Strategy Officer of Standard BioTools Inc. from January 2024 to July 2024. He previously served as interim Chief Executive Officer of SomaLogic, Inc., a proteomics company, from March 2023 until SomaLogic’s acquisition by Standard BioTools in January 2024. Mr. Taich served as SomaLogic’s Chief Business Officer from November 2021 to March 2023 as well as SomaLogic’s Executive Vice President of Life Sciences from April 202